GlassScriptPhysician profile
Heather Miller
NPI 1225456452
$2,559.44
in general payments reported to CMS, 2019-2025
31 companies · $1,320 in 2025
The $1,320 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2021: $176 · 2022: $414 · 2023: $256 · 2024: $267 · 2025: $1,320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,844.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,844.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $896.40 | 2019-2025 | Lynparza, Enhertu, Imfinzi |
| Integra Lifesciences Corporation | $233.99 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Merck Sharp & Dohme LLC | $221.67 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Abbvie INC. | $151.76 | 2025 | |
| Heron Therapeutics, INC. | $127.73 | 2022 | |
| Eisai INC. | $122.45 | 2021-2025 | |
| Daiichi Sankyo INC. | $108.19 | 2025 | Enhertu, Datroway |
| Novartis Pharmaceuticals Corporation | $67.05 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.55 | 2025 | Fruzaqla, Iclusig |
| Ipsen Biopharmaceuticals, INC | $49.31 | 2025 | Onivyde, Somatuline Depot |
| Baxter Healthcare | $47.99 | 2021-2024 | Tisseel |
| Glaxosmithkline, LLC. | $45.42 | 2024-2025 | Jemperli, Zejula |
| Janssen Biotech, INC. | $42.89 | 2025 | Tecvayli, Darzalex, Rybrevant |
| Dendreon Pharmaceuticals LLC | $34.76 | 2025 | Provenge |
| Incyte Corporation | $29.00 | 2025 | Jakafi |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $27.13 | 2025 | Monoferric |
| Beone Medicines USA, INC. | $25.93 | 2025 | Tevimbra |
| Vertex Pharmaceuticals Incorporated | $25.29 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.15 | 2025 | |
| Springworks Therapeutics, INC. | $23.80 | 2025 | Ogsiveo |
| Pfizer INC. | $22.83 | 2025 | |
| Mimedx Group, INC. | $22.73 | 2024 | |
| Corcept Therapeutics | $20.59 | 2025 | Korlym |
| Puma Biotechnology, INC. | $19.47 | 2025 | |
| Genentech USA, INC. | $17.69 | 2025 | Polivy |
| Astellas Pharma US INC | $17.33 | 2025 | Padcev |
| Organogenesis INC. | $17.32 | 2024 | |
| Helsinn Therapeutics (U.S.), INC. | $16.36 | 2022 | |
| Sumitomo Pharma America, INC. | $16.33 | 2025 | Orgovyx |
| Coopersurgical, INC. | $15.74 | 2023 | Endosee |
| Clovis Oncology, INC. | $12.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.